Back to News
Market Impact: 0.25
Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Beats Revenue Estimates
Source: zacks.com
Corporate EarningsHealthcare & BiotechCompany FundamentalsAnalyst Estimates
Dianthus Therapeutics reported a quarterly loss of $0.81 per share, 19 cents narrower than the Zacks Consensus Estimate of a $1.00 loss. The loss also narrowed from $0.97 per share a year earlier.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
DNTH0.35
More News
- Dianthus Therapeutics earnings up next as trial data looms
- NextDC shares surge 43% after Goodman, Digital Realty stake purchases
- Asian chip stocks slide as disappointing Qualcomm, Arm earnings weigh
- Snap shares fall over 10% on third-quarter earnings miss
- ‘Seismic’ blue wave triggers the sinking of oil prices, energy stocks, and the chances of power permitting reform
- Softbank’s $5.4 bln takeover of ABB robotics unit blocked by China- FT